On June 2, Ge Longhui (688506.SH) announced that the innovative biopharmaceutical BL-B01D1 (EGFR×HER3-ADC) monotherapy independently developed by the company for injectable BL-B01D1 (EGFR×HER3-ADC) monotherapy for locally advanced or metastatic EGFR wild non-small cell lung cancer that has previously been treated with anti-PD-1/PD-L1 monoclonal antibodies and failed platinum-containing chemotherapy treatment has recently completed the first case of participants.
百利天恒(688506.SH)：BL-B01D1(EGFR×HER3-ADC)用于局部晚期或转移性EGFR野生型非小细胞肺癌III期临床试验完成首例受试者入组
Bailey Tianheng (688506.SH): BL-B01D1 (EGFR×HER3-ADC) for locally advanced or metastatic EGFR wild-type non-small cell lung cancer phase III clinical trial completed the first patient enrollment
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated